Moderna-Merck Cancer Vaccine Wins, Stock Doubles
Moderna and Merck's mRNA cancer vaccine met its primary endpoint in a Phase 3 melanoma trial, and the stock's reported jump drew 96 recent mentions.
What's happening
Moderna and Merck's mRNA cancer vaccine met its primary endpoint in a Phase 3 melanoma trial, cutting recurrence. NDTV, Axios and the WSJ covered the result, and Axios and the WSJ described the shares as soaring. Hindustan Times reported Moderna's stock jumping 120%, and the story-day close was $133.32.
The numbers
The story-day close was $133.32, and outlet figures for the share move ranged from 120% to 150%. Chatter stats: velocity 11.0, breadth 5 and 96 recent mentions.
Our read
Verdict: real. This is as unambiguous as market signals get this cycle - big trial win, immediate and massive price confirmation across independent sources. Watch for full data detail and whether Merck commits to a broader neoantigen pipeline off this result.
Context
Sort Brick has no earlier Moderna story in this set, so there is no prior verdict to compare. On the story day, $133.32 sat 66% of the way up its 30-day range of $53.86 to $174.38, and 68% of the way up its 90-day range of $45.64 to $174.38. Across the 30-day window the stock was up 123.5%. On the fifth trading day after, it closed at 142.77, up 7.1% from the story-day close. After 20 trading days it closed at 154.04, up 15.5%. That is price history only and does not show what caused either move.
Sources we checked
- Moderna-Merck Breakthrough Cancer Vaccine Shows Promise In Clinical Trial For Melanoma Treatment โ NDTV
- Moderna stock jumps 120% after cancer vaccine trial win: What investors need to know | Hindustan Times โ Hindustan Times
- Moderna and Merck shares soar on mRNA cancer vaccine โ Axios
- Moderna Hopes mRNA Cancer Vaccine Will Be a Disruptive Breakthrough โ cnbeta.com.tw
- Moderna Stock Soars on Cancer Vaccine Success โ WSJ
- Moderna, Merck breakthrough could usher in wave of cancer vaccines โ japantimes.co.jp
- A bump in the #Biotech stocks in recent trading sessions, lifting the likes of Oxford @nanoporetech.com@bsky.brid.gy , partly also due to good news by #Moderna โ @albertvilella.bsky.social@bsky.brid.gy
- Moderna and Merck's cancer vaccine raises new treatment hopehttps://www.theglobeandmail.com/world/video-moderna-and-mercks-cancer-vaccine-raises-new-treatment-h โ @globeandmail@flipboard.com
See today's live board
This story is frozen as published on August 20, 2026. The live board shows what is moving right now, scored against real money.
Open this story live โ See today's live boardMore Stocks stories
- Walmart's Big Earnings Test Looms, Verdict Still Out August 20, 2026
- YouTube Pays Creators To Skip Netflix, Stock Shrugs August 20, 2026
- Evergrande Founder Gets Life, Not A Trade August 20, 2026
- Rivian climbs on raised delivery guidance, not headlines August 20, 2026
- Marvell's Google TPU deal is worth more than the noise August 20, 2026
- Strategy rallies 12% on a quarter that lost $8.2B August 20, 2026
Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything โ you decide.